SCHEMBL3159372

SCHEMBL3159372

Cc1ccccc1C1CC(=O)C=CN1C(=O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
HTR2C P28335 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CYP2C19 P33261 1/20 0.41
HPGD P15428 1/20 0.41
MITF O75030 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNA1I Q9P0X4 1/20 0.40
ELANE P08246 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490272 0.87 PKM (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL25193664 0.86 SMN1; SMN2 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30287351 0.86 SMN1; SMN2 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL25205078 0.86 PSEN1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3159251 0.84 P2RX7 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20449200 0.84 P2RX7 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8658861 0.81 HTR2C (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL757756 0.81 HTR2C (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5769009 0.80 PSEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2706680 0.80 P2RX7 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513814-B1 NOVEL PIPERIDINE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2010-03-17 EP disclosed
US-7619092-B2 Piperidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-17 US disclosed
EP-1513814-A4 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO (JP) 2007-03-14 EP disclosed
US-20050239829-A1 Novel piperidine compound TANABE SEIYAKU CO. LTD. (JP) 2005-10-27 US disclosed
EP-1513814-A1 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-03-16 EP disclosed
WO-2003099787-A1 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239829-A1 Novel piperidine compound EP300, BRD1, CBR3 PSEN1 3482/4885PSEN2 3520/4885APH1B 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.